Skip to content
value.today

DMC Biotechnologies, Inc.

🇺🇸 Boulder, Colorado, USABiotechnologyFounded 2017
Total raised
$47 M
5 rounds on record
Latest round
$1 M
Dec 2025
First round on record
Jan 2018
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of DMC Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$1 MNo. 5Under $2 million

DMC Biotechnologies, Inc.: Raise no. 5, Dec 2025

Investors in this round

7 investors had bought by the notice of Dec 30, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jim Flatt · Executive Officer, Director
  • Josh Yelen · Executive Officer
  • Alastair Cooper · Director
  • Doug Cameron · Director
  • Josko Bobanovic · Director
  • K'Lynne Johnson · Director
  • Matthew Lipscomb · Director
  • Rob van der Meij · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jim Flatt, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 30, 2025. Read the notice at the SEC.

equity, debt, optionsSEC
Apr 2025$5 MNo. 4$2 to $10 million

DMC Biotechnologies, Inc.: Raise no. 4, Apr 2025

Investors in this round

9 investors had bought by the notice of Apr 23, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jim Flatt · Executive Officer, Director
  • Josh Yelen · Executive Officer
  • Alastair Cooper · Director
  • Doug Cameron · Director
  • Josko Bobanovic · Director
  • K'Lynne Johnson · Director
  • Matthew Lipscomb · Director
  • Rob van der Meij · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jim Flatt, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 23, 2025. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2021$34 MNo. 3$10 to $50 million

DMC Biotechnologies, Inc.: Raise no. 3, Nov 2021

Investors in this round

12 investors had bought by the notice of Dec 10, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$34 M of $44 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Lipscomb · Executive Officer, Director
  • Alastair D. Cooper · Director
  • Carolyn D. Fritz · Director
  • Doug D. Cameron · Director
  • Josko D. Bobanovic · Director
  • Michael D. Lynch · Director
  • Rob D. van der Meij · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold includes equity issued upon the conversion of outstanding principal and interest of convertible promissory notes.”

Signed by Matthew Lipscomb, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2021. Read the notice at the SEC.

equitySEC
Jun 2019$5 MNo. 2$2 to $10 million

DMC Biotechnologies, Inc.: Raise no. 2, Jun 2019

Investors in this round

3 investors had bought by the notice of Jun 27, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Lipscomb · Executive Officer, Director
  • Carolyn D. Fritz · Director
  • Josko D. Bobanovic · Director
  • Michael D. Lynch · Director
  • Rob D. van der Meij · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Lipscomb, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 27, 2019. Read the notice at the SEC.

equitySEC
Jan 2018$3 MNo. 1$2 to $10 million

DMC Biotechnologies, Inc.: Raise no. 1, Jan 2018

Investors in this round

3 investors had bought by the notice of Mar 15, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew L. Lipscomb · Executive Officer, Director
  • Carolyn D. Fritz · Director
  • Michael D. Lynch · Director
  • Rob D. van der Meij · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offer and Sale of Series Seed Preferred Stock and Series Seed Preferred Stock Warrants (and the shares issuable thereunder)”

Signed by Matthew L. Lipscomb, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 15, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • DMC Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: DMC Biotechnologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of DMC Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by DMC Biotechnologies, Inc.
NameRoleNamed in
Jim FlattExecutive officerDec 2025
Josh YelenExecutive officerDec 2025
Matthew LipscombExecutive officerDec 2021
Matthew L. LipscombExecutive officerMar 2019
Alastair CooperDirectorDec 2025
Doug CameronDirectorDec 2025
Jim FlattDirectorDec 2025
Josko BobanovicDirectorDec 2025
K'Lynne JohnsonDirectorDec 2025
Matthew LipscombDirectorDec 2025
Rob van der MeijDirectorDec 2025
Alastair D. CooperDirectorDec 2021
Carolyn D. FritzDirectorDec 2021
Doug D. CameronDirectorDec 2021
Josko D. BobanovicDirectorDec 2021
Michael D. LynchDirectorDec 2021
Rob D. van der MeijDirectorDec 2021
Matthew L. LipscombDirectorMar 2019